CNS Oncology (Sep 2023)

High-dose bevacizumab for radiation-induced brain necrosis: a case report

  • Emmanouil Panagiotou,
  • Andriani Charpidou,
  • Eleni Fyta,
  • Vasiliki Nikolaidou,
  • Lamprini Stournara,
  • Alexandros Syrigos,
  • Ioannis Gkiozos

DOI
https://doi.org/10.2217/cns-2023-0002
Journal volume & issue
Vol. 12, no. 3

Abstract

Read online

Radiation-induced brain necrosis (RIBN) is a common adverse event from radiation therapy. We present a case of a 56-year-old man, diagnosed with non-small-cell lung cancer with brain metastases 2 years prior, for which he had received whole brain radiotherapy and brain stereotactic radiosurgery, who presented to the oncology unit with headache, dizziness and abnormal gait. MRI of the brain revealed radiological worsening of a cerebellar mass, including edema and mass effect. After a multidisciplinary tumor board meeting, the patient was diagnosed with RIBN and received 4 cycles of high-dose bevacizumab, with complete symptom resolution and significant radiological response. We report the successful use of a high-dose, shorter-duration treatment protocol of bevacizumab for RIBN.

Keywords